Form 4: Beam Therapeutics Exec Sells Shares for Tax Obligations

Beam Therapeutics' SVP of Finance and Treasurer, Bethany J. Cavanagh, sold 467 shares of common stock at $24.53 per share to cover tax withholding obligations.

Summary

• Bethany J. Cavanagh, SVP, Finance and Treasurer of Beam Therapeutics Inc., reported a transaction involving the company's common stock.
• On October 1, 2025, 467 shares of common stock were disposed of at a price of $24.53 per share.
• The sale was a non-discretionary transaction to cover tax withholding obligations upon the vesting of restricted stock units (RSUs).
• These RSUs were granted under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on September 30, 2021, and September 30, 2024.
• The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2024.
• Following this transaction, Bethany J. Cavanagh beneficially owns 44,045 shares of Beam Therapeutics common stock directly.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale by an executive to cover tax obligations upon RSU vesting, which is a neutral event and does not indicate a change in company fundamentals or management's outlook.

Positives

• The vesting of restricted stock units indicates continued employment and prior equity compensation for a key executive.
• The transaction was non-discretionary and pre-planned under a Rule 10b5-1 trading plan, suggesting a routine financial event rather than a reactive sale.

Negatives

• No specific negative aspects are indicated by this routine, tax-related insider transaction.

Future Outlook

This Form 4 filing does not provide any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This is a routine insider transaction, common for executives who receive equity compensation and need to cover tax obligations upon vesting. It does not reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine, non-discretionary transaction by an executive for tax purposes, not indicative of a change in confidence or company performance.

Key Dates

Recommendation

The transaction reported is a routine, non-discretionary sale of shares by an executive to cover tax withholding obligations upon the vesting of restricted stock units. This type of insider transaction is common and does not typically signal a change in management's confidence in the company's future prospects or warrant a change in investment recommendation based solely on this filing.

Keywords

Beam Therapeutics, BEAM, Insider Trading, Form 4, Stock Sale, Tax Withholding, Restricted Stock Units, 10b5-1 Plan, Bethany Cavanagh